HURWITZ EDWARD 4

What Happened

• Edward Hurwitz, a director of MacroGenics (MGNX), reported derivative activity and RSU awards around the company’s 2026 annual meeting. On 2026-05-18 he recorded an exercise/conversion of 3,750 derivative units (acquired) and a corresponding 3,750-share disposition reported at $0. On 2026-05-19 he was granted/awarded 3,750 RSUs and 22,000 RSUs (total 25,750 RSUs) reported at $0.
• The transactions show conversion/vesting and new RSU awards rather than open-market buying or selling for cash. The reported $0 values indicate these were equity awards/settlements rather than priced market trades.

Key Details

• Transaction dates and prices:
  • 2026-05-18: Exercise/conversion (M) — 3,750 shares acquired (N/A price). Same date: 3,750 shares disposed at $0 (reported as derivative).
  • 2026-05-19: Grant/award (A) — 3,750 RSUs @ $0; Grant/award (A) — 22,000 RSUs @ $0.
• Shares owned after transaction: Not specified in the filing excerpt provided.
• Notable footnotes:
  • F1: Each RSU represents a contingent right to one share.
  • F2: The RSUs vested on May 18, 2026 (one day before the May 19 annual meeting).
  • F3: RSUs generally vest one year after grant or the day before the next annual meeting if earlier.
  • F4: Options vest monthly in cumulative 1/12 increments starting one month from grant.
• Filing timeliness: Form 4 was filed on 2026-05-20 for transactions on 2026-05-18/19 — filed within the typical two-business-day reporting window (not marked late).

Context

• These entries reflect insider award/vesting and conversion activity rather than open-market purchases or sales. The 3,750-share $0 disposition reported on the same day as the exercise/conversion is consistent with tax withholding or net settlement practices commonly used when RSUs vest, though the filing itself shows only the $0 disposal (no cash sale). Awards and exercises of this type are routine compensation/vesting events and do not necessarily indicate a change in insider sentiment.